Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Anticancer Agents Med Chem. 2017;17(6):813–820. doi: 10.2174/1871520616666160923093959

Figure 6.

Figure 6

TLR2 and VEGFR dependent pathways independently promote angiogenesis and tumor growth that can be inhibited by a monoclonal anti-CEP antibody and the anti-VEGF monoclonal antibody Avastin respectively.